ABOUT OCEANA

Oceana Therapeutics is a privately owned, global healthcare company committed to commercializing best-in-class therapeutics with a focus on colorectal, gastroenterology and urological diseases.

With executive offices in Edison, New Jersey and European operations headquartered in Dublin, Ireland, Oceana Therapeutics is exceptionally well positioned to actively pursue worldwide opportunities to identify, acquire, and maximize the therapeutic value of in-market and late-stage development products addressing unmet and under-satisfied medical needs.

Founded in 2008 and led by industry veterans John T. Spitznagel, Chairman & CEO, and David S. Tierney, MD, President and COO, Oceana has brought together a highly experienced team of life science professionals, many having previously worked together in successfully pioneering the BUY & BUILD, SEARCH & DEVELOP* model of acquiring and developing specialty pharmaceuticals.  Supported by the strength of its management team and the breadth of its global resources, Oceana is redefining and significantly advancing that growth model to set new standards of therapeutic excellence for achieving optimal outcomes and making a difference in patient lives. 

To this end, Oceana Therapeutics has broadened the product acquisition, development, and commercialization model beyond the U.S. to encompass international product opportunities.  Additionally, the model has been expanded to include a greater range of specialty therapeutics, including devices, pharmaceuticals, and diagnostics.  Oceana’s strategic focus centers on specialty therapeutics to enable healthcare providers to better tailor a patient’s treatment for optimum efficacy and outcomes. 

The Oceana team is dedicated to the concept of Optimal Outcomes for all participants in the management of healthcare, including patients, medical providers and health insurance plans.  Oceana’s ongoing goal is to broaden therapeutic options for achieving optimal outcomes and improved patient quality of life — whether by reducing demand for surgery, increasing mobility, limiting or eliminating hospitalization or emergency care, and reducing pain.

* Registered Service Mark of Esprit Pharma,Inc. acquired in 2007 by Allergan Inc.